<DOC>
	<DOCNO>NCT02868814</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy safety pregabalin sustain release tablet versus placebo fibromyalgia</brief_summary>
	<brief_title>The Efficacy Safety Pregabalin Release Tablets Treatment Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients meet 1990 American College Rheumatology ( ACR ) criterion fibromyalgia ( ie , widespread pain present least 3 month , pain least 11 18 specific tender point site ) . Patients complete least 4 pain diary within last 7 day average pain score must ≥4 , score ≥40 mm Visual Analogue Scale ( VAS ) screen randomization . Patients severe pain may confound assessment selfevaluation pain associate fibromyalgia . Patients inflammatory muscle rheumatologic disease fibromyalgia , active infection , untreated endocrine disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>